Testing onvansertib plus chemo for first-line advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called onvansertib combined with standard chemotherapy (NALIRIFOX) as the first treatment for advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to see if adding onvansertib helps shrink tumors or slow the cancer better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pancreatic cancer that has spread or cannot be removed by surgery.
- You have not had any chemotherapy or other cancer treatment for metastatic disease before.
- You are willing to have a tumor sample tested (from a past biopsy or a new one).
- You are generally healthy enough for daily activities (ECOG score 0 or 1).
- Your blood counts and organ function are within certain safe limits (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial tests a new drug combination for people whose pancreatic cancer has grown after their first treatment. The goal is to see if it can help shrink tumors or slow the disease.
This trial tests a combination of anlotinib (a targeted drug), benmelstobart (an immunotherapy), and AG chemotherapy as a first treatment for advanced pancreatic cancer that has spread to other parts of the body. The goal is to see if this triple therapy can help shrink or control the cancer better than standard treatments.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.